Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05892289
Other study ID # SYSKY-2022-275-02
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 10, 2023
Est. completion date December 10, 2026

Study information

Verified date May 2023
Source Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Yang bin, associate professor
Phone 13798163278
Email yyzsu@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Proximal early gastric cancer can choose radical total gastrectomy or proximal gastrectomy. The patients have poor nutritional status and quality of life after total gastrectomy. Compare to total gastrectomy, the nutritional status can improve after proximal gastrectomy . But if use simple esophagogastric anastomosis for proximal gastrectomy, the incidence of postoperative reflux esophagitis is high, which seriously affects the quality of life, and the short-term outcome is poorer than the total gastrectomy. If the incidence of postoperative reflux esophagitis can be reduced, proximal gastrectomy would be the treatment choice for proximal early gastric cancer, which may more improve both quality of life and nutritional condition than total gastrectomy. Double-flap technique is a new surgical reconstruction procedure between esophagus and remnant stomach. It can reduce the occurrence of reflux oesophagitis through reconstruction a simulative cardia. At present, the technique has been carried out in some hospitals in China but still lack large-scale prospective studies and evidence of evidence-based medicine. At present, some retrospective studies have shown that robotic assisted proximal gastrectomy with double-flap technique is safe and effective, and the learning curve is shorter than laparoscopic surgery. The applicant have finished two robotic assisted proximal gastrectomy with double-flap technique cases. Two patients recovered well after surgery, with no occurrence of anastomotic leakage or stenosis and the postoperative quality of life was good. Now we plan to conduct a multi-center, single arm study on proximal early gastric cancer patients(T1N0-1M0 and T2N0M0) to evaluate the feasibility of robotic assisted proximal gastrectomy with double-flap technique , and to evaluate the surgical and oncological safety of this surgical method. Aim to provide initial evidence of evidence-based medicine for its clinical application..


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 42
Est. completion date December 10, 2026
Est. primary completion date December 10, 2026
Accepts healthy volunteers No
Gender All
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria: 1. 20 years = age = 80 years 2. The primary gastric lesions were located in the proximal third of the stomach 3. histologically proven gastric adenocarcinoma (by preoperative gastrofiberscopy) 4. clinical stage IA (T1N0M0) or IB (T1N1M0 / T2N0M0) according to the 8th edition of the American Joint Committee on Cancer System(Clinical stage was determined based on the finding of endoscopic ultrasonography and/or thoraco-abdominal contrast-enhanced computed tomography) 5. scheduled for robotic assisted proximal gastrectomy with D1+/D2 lymphadenectomy, and possible for R0 surgery by this procedures (Lymphadenectomy is performed on the basis of the criteria of the Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition).). 6. The preoperative American Society of Anesthesiologists (ASA) physical status was I-III; 7. The patient's cardiopulmonary function can tolerate robotic assisted surgery; 8. The subjects have signed the informed consent form. Exclusion Criteria: 1. history of upper abdominal surgery and not suitable for robotic assisted surgery 2. the tumor invades the esophagus 3cm above gastro-esophageal junction (Z-line) 3. with other malignant diseases or have suffered from other malignant diseases within 5 years 4. Excessive tension for esophagogastric anastomosis and require changing the reconstruction procedure 5. women are pregnant or in lactation period 6. Suffering from serious mental illness 7. history of continuous systemic corticosteroid or immunosuppressive drug treatment within 1 month

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Robotic assisted proximal gastrectomy with double-flap technique
Patients in this group receive robotic assisted proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA:Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9,11p;D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9,11p and 11d).The double-flap technique is used for the digestive tract reconstruction.

Locations

Country Name City State
China Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Guangzhou Guangdong

Sponsors (16)

Lead Sponsor Collaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University First Affiliated Hospital of Guangxi Medical University, First Affiliated Hospital of Kunming Medical University, First Hospital of China Medical University, Gansu Provincial Hospital, LanZhou University, Liaoning Tumor Hospital & Institute, Qilu Hospital of Shandong University, Qinghai Province Cancer Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Sichuan Cancer Hospital and Research Institute, Sichuan Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Third Affiliated Hospital, Sun Yat-Sen University, Tianjin Medical University Cancer Institute and Hospital, Zunyi Medical College

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Proportion of Patients With Reflux Esophagitis Within 12 Months Postoperatively During follow-up endoscopy 1 year after surgery, reflux esophagitis were graded according to the Los Angeles (LA) classification. 12 months postoperatively
Secondary Quality of Life after Surgery Quality of life(QoL) is evaluated using the European Organization for Research and Treatment of Cancer (EORTC) 30-item core QoL (QLQ-C30 ver.3.0). Higher scores mean a worse outcome. Follow-up evaluations are performed 3, 6 and 12 months postoperatively
Secondary Gastrointestinal Symptoms after Surgery gastrointestinal symptoms are assessed by Gastrointestinal Quality of Life Index (GIQLI) questionnaires. Higher scores mean a better outcome. Follow-up evaluations are performed 3, 6 and 12 months postoperatively
Secondary Changes in total protein at Follow-up blood total protein(g/L) levels Follow-up evaluations are performed 3, 6 and 12 months postoperatively.
Secondary Changes in serum albumin at Follow-up blood serum albumin(g/L) levels Follow-up evaluations are performed 3, 6 and 12 months postoperatively.
Secondary Changes in prealbumin at Follow-up blood prealbumin(g/L) levels Follow-up evaluations are performed 3, 6 and 12 months postoperatively.
Secondary Changes in hemoglobin at Follow-up blood hemoglobin(g/L) levels Follow-up evaluations are performed 3, 6 and 12 months postoperatively.
Secondary Changes in Vitamin B12 at Follow-up blood Vitamin B12(µg/ml) levels Follow-up evaluations are performed 3, 6 and 12 months postoperatively.
Secondary Late Postoperative Morbidity adhesive ileus, anastomosis stenosis, malnutrition, dumping syndrome. All postoperative complications are classified according to the Clavien-Dindo(CD) classification standard. Follow-up evaluations are performed 3, 6 and 12 months postoperatively.
Secondary Early Postoperative Morbidity operation wound with seroma, hematoma, infection, dehiscence, or evisceration, anastomotic leakage, anastomotic bleeding, abdominal bleeding, abdominal abscess, intestinal obstruction morbidity, gastrointestinal bleeding, gastroparesis, postoperative pancreatitis, pancreatic fistula, chylous leakage, lung morbidity, cerebrovascular morbidity, cardiovascular morbidity, deep vein thrombosis, cholecystitis, liver dysfunction, kidney dysfunction. All postoperative complications are classified according to the Clavien-Dindo(CD) classification standard. From surgery to discharge, up to 30 days
Secondary Short-term Clinical Outcome After Surgery time to pass gas(hours) From surgery to discharge, up to 30 days
Secondary Short-term Clinical Outcome After Surgery time to oral intake(hours) From surgery to discharge, up to 30 days
Secondary Short-term Clinical Outcome After Surgery time to indwell gastric tube(hours) From surgery to discharge, up to 30 days
Secondary Short-term Clinical Outcome After Surgery length of postoperative hospitalisation(days) From surgery to discharge, up to 30 days
Secondary Surgical Characteristics operative time(minutes) 24 hours postoperatively
Secondary Surgical Characteristics time for reconstruction the digestive tract(minutes) during surgery 24 hours postoperatively
Secondary Surgical Characteristics blood loss during surgery(ml) 24 hours postoperatively
Secondary Quality of Life postoperatively Quality of life(QoL) is evaluated using the European Organization for Research and Treatment of Cancer (EORTC) gastric cancer module (QLQ-STO22) questionnaire. Higher scores mean a worse outcome. Follow-up evaluations are performed 3, 6 and 12 months postoperatively
Secondary Pathological Characteristics R0 resection rate. R0 resection represents complete resection of the tumor, meaning there is no residual tumor. 1 week postoperatively
Secondary Pathological Characteristics lymph nodes dissection extent for each patient in the surgery 1 week postoperatively
Secondary Pathological Characteristics number of dissected lymph nodes for each patient in the surgery 1 week postoperatively
Secondary body mass index postoperatively body mass index(kg/m^2) Follow-up evaluations are performed 3, 6 and 12 months postoperatively.
Secondary pain assessment postoperatively We measured the pain score using visual analog scale(VAS) at 24 h after the surgery is completed. Higher scores mean a worse outcome. Day 1 postoperatively
Secondary Proportion of participants die after surgery mortality rate From surgery to discharge, up to 30 days
Secondary Proportion of participants need to rehospitalized after surgery rehospitalization rate From surgery to discharge, up to 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT04351867 - A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer Phase 3
Recruiting NCT02887612 - ctDNA for Prediction of Relapse in Gastric Cancer
Active, not recruiting NCT02930291 - The Effect of Preoperative Inflammation-based Scores on Postoperative Morbidity and Mortality for Laparoscopic Gastrectomy
Completed NCT02649348 - Effects of Prehabilitation in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome N/A
Recruiting NCT02310230 - An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy N/A
Active, not recruiting NCT01609309 - Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01) Phase 3
Completed NCT00375999 - Docetaxel and Epirubicin in Advanced Gastric Cancer Phase 2
Completed NCT00382720 - Docetaxel and Oxaliplatin in Gastric Cancer Phase 2
Completed NCT00980382 - A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma Phase 1/Phase 2
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Active, not recruiting NCT05602935 - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Phase 2
Recruiting NCT05033392 - PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer Phase 2
Completed NCT04539769 - Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes Phase 2
Active, not recruiting NCT02845986 - Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer Phase 2
Active, not recruiting NCT02930278 - The Effect of Preoperative Hemotologic Markers on Postoperative Long-term and Short-term Outcomes for Laparoscopic Gastrectomy
Completed NCT02902575 - The Safety and Feasibility of Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer After Neoadjuvant Chemotherapy N/A
Recruiting NCT04222114 - Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis Phase 3
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4